MCID: ACR014
MIFTS: 44

Acral Lentiginous Melanoma malady

Categories: Rare diseases, Cancer diseases, Skin diseases

Aliases & Classifications for Acral Lentiginous Melanoma

About this section

Aliases & Descriptions for Acral Lentiginous Melanoma:

Name: Acral Lentiginous Melanoma 11 46 13
Acral Lentiginous Malignant Melanoma of Skin 46
Acral Lentiginous Melanoma, Malignant 11
Malignant Acral Lentiginous Melanoma 11
 
Acral Lentiginous Malignant Melanoma 66
Palmar/plantar Melanoma 46
Subungual Melanoma 46
Alm 46

Classifications:



External Ids:

Disease Ontology11 DOID:6367

Summaries for Acral Lentiginous Melanoma

About this section
Disease Ontology:11 A skin melanoma that is characterized by slow growth of a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin and occurs on occurs on non hair-bairing surfaces including hands and feet, subungual sites, and fingers or toes.

MalaCards based summary: Acral Lentiginous Melanoma, also known as acral lentiginous malignant melanoma of skin, is related to melanoma and alstrom syndrome, and has symptoms including macule An important gene associated with Acral Lentiginous Melanoma is NRAS (Neuroblastoma RAS Viral Oncogene Homolog), and among its related pathways are Thyroid cancer and Vemurafenib Pathway, Pharmacodynamics. Affiliated tissues include skin, lymph node and brain, and related mouse phenotypes are craniofacial and integument.

Wikipedia:69 Acral lentiginous melanoma is a kind of lentiginous skin melanoma. Melanoma is a potentially serious... more...

Related Diseases for Acral Lentiginous Melanoma

About this section

Diseases related to Acral Lentiginous Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 104)
idRelated DiseaseScoreTop Affiliating Genes
1melanoma32.3KIT, NRAS
2alstrom syndrome11.2
3leukemoid reaction10.5KIT, NRAS
4lateral medullary syndrome10.5KIT, NRAS
5acute myeloid leukemia, somatic dnmt3a-related10.5KIT, TERT
6acute panmyelosis with myelofibrosis10.5KIT, TERT
7mastroiacovo de rosa satta syndrome10.4KIT, NRAS
8pterygium colli mental retardation digital anomalies10.4BRAF, NRAS
9rad51c-related fanconi anemia10.4BRAF, NRAS
10psammomatous meningioma10.4CDKN2A, NRAS
11critical congenital heart disease10.4KIT, NRAS
12vulva fibroepithelial polyp10.4CDKN2A, NRAS
13esophagus leiomyosarcoma10.4KIT, NRAS
14burning mouth syndrome10.4BRAF, NRAS
15adenofibroma10.4CDKN2A, NRAS
16boylan dew greco syndrome10.4CDKN2A, TERT
17toxascariasis10.4CDKN2A, NRAS
18x-linked congenital generalized hypertrichosis10.3CDKN2A, TERT
19spindle cell hemangioma10.3CDKN2A, NRAS
20central centrifugal cicatricial alopecia10.3CDKN2A, TERT
21infiltrative basal cell carcinoma10.3CDKN2A, KIT
22epithelioid cell melanoma10.3BRAF, KIT
23epicardium cancer10.3BRAF, KIT
24pancreatic agenesis10.3CDKN2A, KIT
25localized epiphyseal dysplasia10.3BRAF, NRAS
26split hand split foot malformation autosomal recessive10.3BRAF, CDKN2A
27asrar facharzt haque syndrome10.3CDKN2A, KIT
28stromal keratitis10.2CDKN2A, TERT
29sialolithiasis10.2CDKN2A, KIT
30gastrointestinal neuroendocrine tumor10.2CDKN2A, KIT
31epithelioid leiomyosarcoma10.2KIT, PTEN
32sarcoma10.2
33localized osteosarcoma10.2CDKN2A, KIT
34leopard syndrome 110.2BRAF, NRAS
35desmoplastic infantile astrocytoma10.2CDKN2A, KIT
36multiple spinal canal and spinal cord meningioma10.1CDKN2A, KIT
37angiokeratoma circumscriptum10.1CDKN2A, KIT
38esophagus verrucous carcinoma10.1CDKN2A, PTEN
39early myoclonic encephalopathy10.1CDKN2A, PTEN
40sporadic idiopathic steroid-resistant nephrotic syndrome with minimal changes10.1CDKN2A, PTEN
41compartment syndrome10.1CDKN2A, PTEN
42non-congenital cyst of kidney10.1CDKN2A, PTEN
43pelvic muscle wasting10.1CDKN2A, PTEN
44psoriatic arthritis10.0
45multiple myeloma10.0
46arthritis10.0
47myeloma10.0
48tinea pedis10.0
49basal cell carcinoma10.0
50laryngitis10.0

Graphical network of the top 20 diseases related to Acral Lentiginous Melanoma:



Diseases related to acral lentiginous melanoma

Symptoms for Acral Lentiginous Melanoma

About this section

UMLS symptoms related to Acral Lentiginous Melanoma:


macule

Drugs & Therapeutics for Acral Lentiginous Melanoma

About this section

Drugs for Acral Lentiginous Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CediranibPhase 2919933475
Synonyms:
288383-20-0
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline
4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline
790713-41-6
AKOS005145767
AZD 2171
AZD-2171
AZD2171
AZD2171, Recentin, Cediranib
CHEMBL491473
CID9933475
 
Cediranib
Cediranib (USAN/INN)
Cediranib maleate
D08881
EC-000.2328
Kinome_3318
M6294
NSC-732208
Recentin
S1017_Selleck
UNII-NQU9IPY4K9
ZD-2171
cediranib
2Imatinib MesylatePhase 2588123596
3
Maleic acidPhase 2292110-16-7444266
Synonyms:
(2Z)-2-Butenedioate
(2Z)-2-Butenedioic acid
(2Z)-Butene-2-dioate
(2Z)-Butene-2-dioic acid
(2Z)-but-2-enedioate
(2Z)-but-2-enedioic acid
(Z)-2-Butenedioate
(Z)-2-Butenedioic acid
(z)-butenedioate
(z)-butenedioic acid
2-Butenedioate
2-Butenedioic acid
Cis-butenedioate
Cis-butenedioic acid
 
H2male
Kyselina maleinova
MAE
Maleate
Maleic acid
Maleic acid [NA2215]
Maleinic acid
Malenic acid
Malezid CM
Scotchbond multipurpose etchant
Toxilic acid
cis-1,2-Ethylenedicarboxylic acid
cis-2-Butenedioate
cis-2-Butenedioic acid
cis-But-2-enedioate
cis-But-2-enedioic acid
4
TrametinibPhase 2115871700-17-311707110
Synonyms:
GSK 1120212
GSK1120212
JTP 74057
JTP-74057
 
MEK Inhibitor GSK1120212
Mekinist
Trametinib Dimethyl Sulfoxide
Trametinibum
trametinib
5
DabrafenibPhase 27544462760, 44516822
Synonyms:
BRAF inhibitor GSK2118436
Dabrafenib
 
GSK2118436
GSK2118436a
Tafinlar
dabrafenib
6
DasatinibPhase 2276302962-49-83062316
Synonyms:
(18F)-N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
1N1
2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide
302962-49-8
AC1MI3ET
AC1Q2P0C
AmbotzLS-1203
Anhydrous dasatinib
BCB03_000715
BMS 354825
BMS dasatinib
BMS-354825
BMS-354825, Sprycel, BMS354825, Dasatinib
BMS354825
C488369
CHEBI:49375
CHEMBL1421
CID3062316
D03658
DB01254
Dasatinib
Dasatinib (USAN)
Dasatinib (anh.)
Dasatinib [USAN]
Dasatinib anhydrous
Dasatinib, BMS 354825
Dasatinibum
EC-000.2122
 
EN002710
FT-0084503
I14-1972
Kinome_3650
LS-186641
LS-187028
LS-187773
MolPort-003-846-143
N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE
N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide
N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide, monohydrate
N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide
N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide
NCGC00181129-01
NSC-732517
NSC732517
S1021_Selleck
SPRYCEL (TN)
Sprycel
Spyrcel
UNII-X78UG0A0RN
anh. dasatinib
dasatinib
dasatinib (anhydrous)
dasatinibum
nchembio.117-comp11
nchembio.162-comp4
nchembio.332-comp1
7
SunitinibPhase 2493341031-54-7, 557795-19-45329102
Synonyms:
(2S)-2-hydroxybutanedioic acid
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
1H-Pyrrole-3-carboxamide, N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-, (2S)-hydroxybutanedioate (1:1)
326914-13-0
341031-54-7
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
557795-19-4
AC1NS62J
AC1O5CMQ
AKOS005145765
Butanedioic acid, hydroxy-, (2S)-, compd. with N-(2-(diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (1:1)
CHEBI:38940
CHEBI:550864
CHEMBL1567
CHEMBL535
CID5329102
CID6456015
D06402
D08552
DB01268
DB07417
EN002687
FT-0083555
FT-0083556
I01-1229
K00588a
KS-5022
LS-186078
LS-187023
LS-187648
MolPort-003-986-763
N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
NCGC00164631-01
 
NSC736511
NSC750690
PDGF TK antagonist
PHA-290940AD
PNU-290940AD
S1042_Selleck
ST51053712
SU 011248
SU 11248
SU-010398
SU-011248 L-malate salt
SU-11248
SU-11248 L-malate salt
SU-11248J
SU-12662
SU010398
SU011248
SU011248 L-malate salt
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (free base)
Sunitinib malate
Sunitinib malate (JAN/USAN)
Sunitinib malate [USAN]
Sunitinibum
Sutent
Sutent (TN)
Sutent, SU-11248
TL8002546
UNII-LVX8N1UT73
UNII-V99T50803M
sunitinib
sunitinibum
8
pembrolizumabPhase 23551374853-91-4
Synonyms:
Keytruda
 
MK-3475
lambrolizumab
9tyrosineNutraceuticalPhase 2633
10
GanciclovirPhase 114682410-32-03454
Synonyms:
106931-35-5
107910-75-8 (mono-hydrochloride salt)
2'-NDG
2'-Nor-2'-deoxyguanosine
2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol
2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-H-purin-6-one
2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-Dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one
2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol
2-amino-9-(1,3-dihydroxypropan-2-yloxymethyl)-3H-purin-6-one
2-amino-9-(2-Hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one
2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-6,9-dihydro-3H-purin-6-one
82410-32-0
86357-12-2
9-((1,3-Dihydroxy-2-propoxy)methyl)guanine
9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine
9-(1,3-DIHYDROXY-PROPOXYMETHANE)GUANINE
9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine
9-[(1,3-dihydroxy-2-propoxy)methyl]guanine
96551-29-0
AC-12604
AC1L1FZ2
AC1Q52OB
AKOS004119898
BB_NC-1042
BIDD:GT0783
BIOLF-62
BPBio1_000877
BSPBio_000797
BW 759
BW 759U
BW-759U
BW-795
BW-B 759U
Biolf 62
CAS-82410-32-0
CCRIS 9212
CHEBI:465284
CHEMBL182
CID3454
CPD000058324
Citovirax
Cymevan
Cymeven
Cymevene
Cytovene
Cytovene (TN)
Cytovene-IV
D00333
DB01004
DRG-0018
EU-0100539
 
G 2536
G2536_SIGMA
GA2
GANCICLOVIR SODIUM
GCV & 1110U81
GCV & MSL
Ganciclovir
Ganciclovir & C34-dgA immunotoxin
Ganciclovir & D5-dgA immunotoxin
Ganciclovir (JAN/USP/INN)
Ganciclovir [USAN:INN:BAN:JAN]
Ganciclovirum
Ganciclovirum [Latin]
Gancyclovir
Guanine, 9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)- and MSL, neutralizing monoclonal antibody
HHEMG
HMS1570H19
HMS2090K08
HSDB 6512
Hydroxyacyclovir
I07-0010
IN1478
LS-73939
Lopac-G-2536
Lopac0_000539
MB3795
MLS000028481
MLS001077349
MolPort-000-758-398
MolPort-002-507-301
NCGC00015471-01
NCGC00015471-02
NCGC00015471-03
NCGC00015471-06
NCGC00093928-01
NCGC00093928-02
NCGC00168567-01
PDSP1_000816
PDSP2_000803
Prestwick0_000839
Prestwick1_000839
Prestwick2_000839
Prestwick3_000839
Prestwick_1068
RS-21592
SAM002548936
SMP2_000038
SMR000058324
SPBio_002718
ST-605
STK801910
UNII-P9G3CKZ4P5
Virgan
Vitrasert
Vitrasert (TN)
ZINC00001505
Zirgan
ganciclovir
nchembio.87-comp3

Interventional clinical trials:

(show all 14)
idNameStatusNCT IDPhase
1AZD2171 in Treating Patients With Recurrent or Stage IV MelanomaCompletedNCT00243061Phase 2
2Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryCompletedNCT00470470Phase 2
3A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has SpreadRecruitingNCT01395121Phase 2
4Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By SurgeryRecruitingNCT00700882Phase 2
5Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive MelanomaRecruitingNCT02083354Phase 2
6Dinaciclib in Treating Patients With Stage IV MelanomaActive, not recruitingNCT00937937Phase 2
7SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous MelanomaActive, not recruitingNCT00577382Phase 2
8Imatinib in Patients With Mucosal or Acral/Lentiginous MelanomaActive, not recruitingNCT00424515Phase 2
9Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged MelanomaActive, not recruitingNCT00788775Phase 2
10Pembrolizumab in Advanced/Metastatic Acral Lentiginous MelanomaNot yet recruitingNCT02875132Phase 2
11Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged MelanomaTerminatedNCT01092728Phase 2
12Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV MelanomaTerminatedNCT01120275Phase 2
13Gene Therapy and Ganciclovir in Treating Patients With Stage IV MelanomaCompletedNCT00005057Phase 1
14Study of Families With MelanomaRecruitingNCT00445783

Search NIH Clinical Center for Acral Lentiginous Melanoma

Genetic Tests for Acral Lentiginous Melanoma

About this section

Anatomical Context for Acral Lentiginous Melanoma

About this section

MalaCards organs/tissues related to Acral Lentiginous Melanoma:

34
Skin, Lymph node, Brain

Animal Models for Acral Lentiginous Melanoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Acral Lentiginous Melanoma:

39 (show all 25)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053828.9BRAF, KIT, MET, NRAS
2MP:00107718.6BRAF, CDKN2A, KIT, NRAS, PTEN
3MP:00011868.6BRAF, CDKN2A, KIT, NRAS, PTEN
4MP:00053898.4BRAF, CDKN2A, KIT, PTEN, TERT
5MP:00053698.0BRAF, CDKN2A, KIT, MET, PTEN
6MP:00053888.0BRAF, CDKN2A, KIT, MET, PTEN
7MP:00053717.9KIT, MET, NRAS, PTEN
8MP:00053907.9BRAF, CDKN2A, KIT, PTEN, TERT
9MP:00053977.9BRAF, CDKN2A, KIT, NRAS, PTEN, TERT
10MP:00053707.7BRAF, CDKN2A, KIT, MET, NRAS, PTEN
11MP:00053807.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN
12MP:00028737.5BRAF, KIT, MET, NRAS, PTEN, TERT
13MP:00053857.4BRAF, CDKN2A, KIT, MET, NRAS, PTEN
14MP:00053917.4BRAF, CDKN2A, KIT, MET, NRAS, PTEN
15MP:00036317.4BRAF, CDKN2A, KIT, MET, PTEN, TERT
16MP:00053877.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
17MP:00053867.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
18MP:00053847.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
19MP:00020067.1BRAF, CDKN2A, KIT, MET, NRAS, PTEN
20MP:00053817.1BRAF, CDKN2A, KIT, MET, NRAS, PTEN
21MP:00107687.0BRAF, CDKN2A, KIT, MET, NRAS, PTEN
22MP:00053796.9BRAF, CDKN2A, KIT, MET, NRAS, PTEN
23MP:00053786.8BRAF, CDKN2A, KIT, MET, NRAS, PTEN
24MP:00053766.6BRAF, CDKN2A, KIT, MET, NRAS, PTEN

Publications for Acral Lentiginous Melanoma

About this section

Articles related to Acral Lentiginous Melanoma:

(show top 50)    (show all 119)
idTitleAuthorsYear
1
Amelanotic acral lentiginous melanoma mimicking diabetic ulcer: a challenge to diagnose and treat. (26679765)
2016
2
Acral Lentiginous Melanoma. (26601870)
2016
3
Acral lentiginous melanoma: who benefits from sentinel lymph node biopsy? (25455840)
2015
4
Reflectance confocal microscopy features of acral lentiginous melanoma: a comparative study with acral nevi. (26428577)
2015
5
The distribution pattern of HMB-45-positive cells is helpful for the diagnosis of early acral lentiginous melanoma in situ. (25773399)
2015
6
Reconstruction of large wounds using a combination of negative pressure wound therapy and punch grafting after excision of acral lentiginous melanoma on the foot. (26173565)
2015
7
Screening for Acral Lentiginous Melanoma in Dark-Skinned Individuals. (26083954)
2015
8
Acral lentiginous melanoma of the foot misdiagnosed as a traumatic ulcer a cautionary case. (25815661)
2015
9
TERT promoter mutation is uncommon in acral lentiginous melanoma. (24588324)
2014
10
Acral lentiginous melanoma treated with topical imiquimod cream: possible cooperation between drug and tumour cells. (25252087)
2014
11
Two Spanish cases of Atypical Melanosis of the Foot, an early stage of Acral Lentiginous Melanoma in situ. (25323966)
2014
12
Prognostic and Clinicopathologic Associations of BRAF Mutation in Primary Acral Lentiginous Melanoma in Korean Patients: A Preliminary Study. (24882974)
2014
13
Acral lentiginous melanoma of the toe treated using Mohs surgery with sparing of the digit and subsequent reconstruction using split-thickness skin graft. (22931051)
2013
14
Psoriatic arthritis with acral lentiginous melanoma: role for methotrexate? (24249911)
2013
15
KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma. (23993026)
2013
16
Clinical presentation of acral lentiginous melanoma: a descriptive study. (22959666)
2013
17
The "spaghetti technique": an alternative to Mohs surgery or staged surgery for problematic lentiginous melanoma (lentigo maligna and acral lentiginous melanoma). (21167406)
2011
18
Acral lentiginous melanoma. (21549241)
2011
19
Acral lentiginous melanoma: a case control study and guidelines update. (21541184)
2011
20
Letter: Acral-lentiginous melanoma: Report of 15 cases. (21272506)
2011
21
Acral lentiginous melanoma in situ: a diagnostic and management challenge. (24281086)
2010
22
Cutaneous involvement in multiple myeloma mimicking acral-lentiginous melanoma. (20466190)
2010
23
Unilateral lichen planus pigmentosus mimicking acral lentiginous melanoma. (20677541)
2010
24
Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. (19380664)
2009
25
Acral lentiginous melanoma of the foot and ankle: A case series and review of the literature. (18822168)
2008
26
Constitutive activation of the phosphatidyl inositol 3 kinase signalling pathway in acral lentiginous melanoma. (17999703)
2008
27
Acral lentiginous melanoma: histopathological prognostic features of 121 cases. (17596173)
2007
28
Acral lentiginous melanoma misdiagnosed as verruca plantaris: a case report. (17083858)
2006
29
Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. (16911282)
2006
30
Case of the month. Pigmented acral-lentiginous melanoma (ALM). (16483079)
2006
31
Acral lentiginous melanoma: an immunohistochemical study of 20 cases. (12709000)
2003
32
An analysis of p16 tumour suppressor gene expression in acral lentiginous melanoma. (10657449)
2000
33
Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. (10754493)
2000
34
Acral lentiginous melanoma. (9879051)
1998
35
Acral lentiginous melanoma of the palm. (9136165)
1996
36
Acral lentiginous melanoma. (8328633)
1993
37
Acral lentiginous melanoma associated with Down's syndrome. (8482754)
1993
38
Ganglioside expression of human melanoma and tumor progression. Ganglioside composition of a plaque and a nodule of acral lentiginous melanoma. (1409417)
1992
39
The current management and prognosis of acral lentiginous melanoma. (1642394)
1992
40
Acral lentiginous melanoma. A report of a case and a review of the literature. (3681672)
1987
41
Improved survival rates of patients with acral lentiginous melanoma treated with hyperthermic isolation perfusion, wide excision, and regional lymphadenectomy. (3518512)
1986
42
Pigmented freckles on the sole of acral lentiginous melanoma in situ. (3908530)
1985
43
Acral lentiginous melanoma and its precursor--heterogeneity of palmo-plantar melanomas. (4047728)
1985
44
Acral lentiginous melanoma and lentigo maligna occurring in Werner's syndrome. (6627991)
1983
45
Acral lentiginous melanoma of the oral cavity. (6841121)
1983
46
Dermatology-epitomes of progress: acral lentiginous melanoma. (18748764)
1981
47
Congenital acral melanocytic nevi clinically stimulating acral lentiginous melanoma. (7287955)
1981
48
Acral lentiginous melanoma. (7389397)
1980
49
Acral lentiginous melanoma. (7396539)
1980
50
A darkly pigmented lesion of a great toe (acral lentiginous melanoma). (864073)
1977

Variations for Acral Lentiginous Melanoma

About this section

Cosmic variations for Acral Lentiginous Melanoma:

8 (show top 50)    (show all 60)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM460BRAFskin,acral,malignant melanoma,acral lentiginousc.1406G>Cp.G469A0
2COSM476BRAFskin,NS,malignant melanoma,acral lentiginousc.1799T>Ap.V600E0
3COSM564NRASskin,NS,malignant melanoma,acral lentiginousc.35G>Ap.G12D0
4COSM1578125KITskin,NS,malignant melanoma,acral lentiginousc.2591C>Tp.S864F0
5COSM1255KITskin,NS,malignant melanoma,acral lentiginousc.1676T>Cp.V559A0
6COSM1430154KITskin,acral,malignant melanoma,acral lentiginousc.1715A>Gp.D572G0
7COSM584NRASskin,acral,malignant melanoma,NSc.182A>Gp.Q61R0
8COSM562NRASskin,acral,malignant melanoma,acral lentiginousc.34G>Tp.G12C0
9COSM1304KITskin,NS,malignant melanoma,acral lentiginousc.1924A>Gp.K642E0
10COSM1290KITskin,acral,malignant melanoma,acral lentiginousc.1727T>Cp.L576P0
11COSM133760KITskin,acral,malignant melanoma,NSc.1942G>Ap.G648S0
12COSM569NRASskin,acral,malignant melanoma,NSc.37G>Cp.G13R0
13COSM253327NRASskin,acral,malignant melanoma,NSc.176C>Ap.A59D0
14COSM580NRASskin,NS,malignant melanoma,acral lentiginousc.181C>Ap.Q61K0
15COSM566NRASskin,NS,malignant melanoma,acral lentiginousc.35G>Tp.G12V0
16COSM467BRAFskin,acral,malignant melanoma,NSc.1781A>Gp.D594G0
17COSM253329BRAFskin,acral,malignant melanoma,NSc.1811G>Ap.W604*0
18COSM12736CDKN2Askin,NS,malignant melanoma,acral lentiginousc.104G>Tp.G35V0
19COSM253324BRAFskin,acral,malignant melanoma,NSc.1349G>Ap.W450*0
20COSM3724522NRASskin,NS,malignant melanoma,acral lentiginousc.184G>Cp.E62Q0
21COSM33972KITskin,NS,malignant melanoma,acral lentiginousc.1915T>Cp.S639P0
22COSM583NRASskin,acral,malignant melanoma,acral lentiginousc.182A>Tp.Q61L0
23COSM36305KITskin,acral,malignant melanoma,NSc.1745G>Ap.W582*0
24COSM110724BAP1skin,NS,malignant melanoma,acral lentiginousc.2090C>Gp.S697C0
25COSM565NRASskin,acral,malignant melanoma,NSc.35G>Cp.G12A0
26COSM1219KITskin,acral,malignant melanoma,NSc.1669T>Cp.W557R0
27COSM1651643KITskin,NS,malignant melanoma,acral lentiginousc.1420G>Ap.V474I0
28COSM29015KITskin,acral,malignant melanoma,acral lentiginousc.1673A>Gp.K558R0
29COSM133774KITskin,acral,malignant melanoma,NSc.1687A>Gp.I563V0
30COSM1273KITskin,acral,malignant melanoma,NSc.1696A>Gp.N566D0
31COSM133756KITskin,acral,malignant melanoma,NSc.2542T>Cp.F848L0
32COSM133763KITskin,acral,malignant melanoma,NSc.1657T>Ap.Y553N0
33COSM144512KITskin,NS,malignant melanoma,acral lentiginousc.1904A>Gp.E635G0
34COSM107986GRIN2Askin,NS,malignant melanoma,acral lentiginousc.1774A>Gp.K592E0
35COSM133765KITskin,acral,malignant melanoma,NSc.1898A>Gp.E633G0
36COSM133757KITskin,acral,malignant melanoma,NSc.2486C>Tp.A829V0
37COSM577NRASskin,NS,malignant melanoma,acral lentiginousc.52G>Ap.A18T0
38COSM133769KITskin,acral,malignant melanoma,NSc.2576T>Cp.L859P0
39COSM563NRASskin,NS,malignant melanoma,acral lentiginousc.34G>Ap.G12S0
40COSM1321KITskin,acral,malignant melanoma,NSc.2466T>Ap.N822K0
41COSM1651644KITskin,NS,malignant melanoma,acral lentiginousc.2449A>Cp.I817L0
42COSM29529RB1skin,NS,malignant melanoma,acral lentiginousc.1411C>Tp.Q471*0
43COSM235682KITskin,acral,malignant melanoma,acral lentiginousc.1965T>Gp.N655K0
44COSM133762KITskin,acral,malignant melanoma,NSc.2450T>Cp.I817T0
45COSM253323BRAFskin,acral,malignant melanoma,NSc.1324G>Ap.G442S0
46COSM1138BRAFskin,NS,malignant melanoma,acral lentiginousc.1823A>Gp.H608R0
47COSM133780KITskin,acral,malignant melanoma,NSc.2531G>Ap.C844Y0
48COSM521KRASskin,NS,malignant melanoma,acral lentiginousc.35G>Ap.G12D0
49COSM1257KITskin,acral,malignant melanoma,acral lentiginousc.1679T>Ap.V560D0
50COSM1166809PTENskin,acral,malignant melanoma,acral lentiginousc.333G>Ap.W111*0

Expression for genes affiliated with Acral Lentiginous Melanoma

About this section
Search GEO for disease gene expression data for Acral Lentiginous Melanoma.

Pathways for genes affiliated with Acral Lentiginous Melanoma

About this section

Pathways related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 28)
idSuper pathwaysScoreTop Affiliating Genes
19.6BRAF, NRAS
29.6BRAF, NRAS
39.6BRAF, NRAS
49.6BRAF, NRAS
5
Show member pathways
9.2BRAF, KIT, NRAS
69.1CDKN2A, NRAS, TERT
7
Show member pathways
9.1BRAF, CDKN2A, NRAS
89.1BRAF, CDKN2A, NRAS
9
Show member pathways
9.0BRAF, NRAS, PTEN
108.8BRAF, CDKN2A, PTEN
118.8BRAF, MET, NRAS
12
Show member pathways
8.5BRAF, KIT, NRAS, PTEN
13
Show member pathways
8.5BRAF, MET, PTEN
14
Show member pathways
8.5BRAF, MET, PTEN
158.4BRAF, CDKN2A, NRAS, PTEN
16
Show member pathways
8.3BRAF, KIT, MET, NRAS
17
Show member pathways
8.3BRAF, KIT, MET, NRAS
188.2KIT, MET, NRAS, PTEN
198.2KIT, MET, NRAS, PTEN
208.1CDKN2A, MET, NRAS, PTEN
21
Show member pathways
8.1BRAF, MET, NRAS, PTEN
22
Show member pathways
8.1BRAF, MET, NRAS, PTEN
23
Show member pathways
8.1BRAF, MET, NRAS, PTEN
24
Show member pathways
7.7BRAF, KIT, MET, NRAS, PTEN
25
Show member pathways
7.6BRAF, CDKN2A, MET, NRAS, PTEN
26
Show member pathways
7.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
277.2BRAF, CDKN2A, KIT, MET, NRAS, PTEN
28
Show member pathways
6.7BRAF, CDKN2A, KIT, MET, NRAS, PTEN

GO Terms for genes affiliated with Acral Lentiginous Melanoma

About this section

Cellular components related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cytoplasmic side of plasma membraneGO:00098989.4KIT, PTEN

Biological processes related to Acral Lentiginous Melanoma according to GeneCards Suite gene sharing:

(show all 7)
idNameGO IDScoreTop Affiliating Genes
1myeloid progenitor cell differentiationGO:000231810.0BRAF, KIT
2negative regulation of endothelial cell apoptotic processGO:20003529.9BRAF, TERT
3replicative senescenceGO:00903999.8CDKN2A, TERT
4regulation of axon regenerationGO:00486799.8BRAF, PTEN
5visual learningGO:00085429.5BRAF, KIT
6long-term synaptic potentiationGO:00602919.3BRAF, PTEN
7MAPK cascadeGO:00001659.2BRAF, KIT, NRAS

Sources for Acral Lentiginous Melanoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
25GTR
26HGMD
27HMDB
28ICD10
29ICD10 via Orphanet
30ICD9CM
31IUPHAR
32KEGG
35MedGen
37MeSH
38MESH via Orphanet
39MGI
42NCI
43NCIt
44NDF-RT
47NINDS
48Novoseek
50OMIM
51OMIM via Orphanet
55PubMed
56QIAGEN
61SNOMED-CT via Orphanet
65Tumor Gene Family of Databases
66UMLS
67UMLS via Orphanet